Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Non-cash Items: 2019-2022

Historic Non-cash Items for C4 Therapeutics (CCCC) over the last 1 years, with Mar 2022 value amounting to $1.7 million.

  • C4 Therapeutics' Non-cash Items rose 214.00% to $1.7 million in Q1 2022 from the same period last year, while for Mar 2022 it was $1.7 million, marking a year-over-year increase of 214.00%. This contributed to the annual value of $1.4 million for FY2021, which is 199.03% up from last year.
  • As of Q1 2022, C4 Therapeutics' Non-cash Items stood at $1.7 million, which was up 22.43% from $1.4 million recorded in Q4 2021.
  • In the past 5 years, C4 Therapeutics' Non-cash Items ranged from a high of $102.6 million in Q4 2020 and a low of $531,248 during Q1 2021.
  • In the last 3 years, C4 Therapeutics' Non-cash Items had a median value of $1.4 million in 2021 and averaged $17.1 million.
  • Per our database at Business Quant, C4 Therapeutics' Non-cash Items surged by 2,037.78% in 2020 and then slumped by 98.67% in 2021.
  • Quarterly analysis of 4 years shows C4 Therapeutics' Non-cash Items stood at $4.8 million in 2019, then spiked by 2,037.78% to $102.6 million in 2020, then plummeted by 98.67% to $1.4 million in 2021, then skyrocketed by 214.00% to $1.7 million in 2022.
  • Its Non-cash Items stands at $1.7 million for Q1 2022, versus $1.4 million for Q4 2021 and $1.1 million for Q3 2021.